NVX-CoV2373(Novavax COVID-19 Vaccine)


Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351(CORRESPONDENCE)
 Shen X, Tang H, Pajon R, et al. 〔N Engl J Med. 2021 Jun 17;384(24):2352-2354〕(査読済み)


Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
 Shinde V, Bhikha S, Hoosain Z, et al. 〔N Engl J Med. 2021 May 20;384(20):1899-1909〕(査読済み)


Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
 Heath P, Galiza EP, Baxter DN, et al. 〔N Engl J Med. 2021 Jun 30;NEJMoa2107659〕(査読済み)


Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
 Khoury DS, Cromer D, Reynaldi A, et al.〔Nat Med. 2021 May 17〕(査読済み)


Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
 Toback S, Galiza E, Cosgrove C, et al. 〔medRxiv. 2021 Jun 13〕(査読前)